Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts
Year: 2019
Type: article
Abstract: Background: Osimertinib is a 3rd-generation, CNS-active EGFR-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitising (EGFRm) and EGFR T790M resistance mutations. Earlier results from the Ph I AURA (NCT01802632) and Ph III FLAURA (NCT02296125) studies have established 1L osimertinib efficacy. We report final efficacy and safety data from two Ph I expansion cohorts who received 1L osimertinib 80 or 160mg for advanced EGFRm NSCLC in AURA.
Source: Annals of Oncology
Authors: J.C.-H. Yang, S.S. Ramalingam, C.K. Lee, T. Kurata, D.-W. Kim, T. John, N. Nogami, Y. Ohe, Y. Rukazenkov, M. Murphy, P.A. Jänne
Institutions: National Taiwan University, Emory University, Winship Cancer Institute, St George Hospital, Kansai Medical University, Seoul National University Hospital, Austin Health, Olivia Newton-John Cancer Research Institute, Shikoku Cancer Center, National Cancer Center Hospital, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,250
OpenAlex ID: W2939206708